Cell therapies

This Perspective provides an overview of recent cardiac cell therapies and their limitations, and argues for the need of deeper mechanistic understanding that informs the use of cells and of next-generation cell-free biologics in cardiac regeneration.

This Review discusses the manufacturing of cell products for clinically advanced cell therapies, and highlights potential manufacturing bottlenecks and solutions towards the cost-effective commercialization of the therapies.

This Review Article provides an overview of chimeric antigen receptors (CARs) for T cells and discusses engineering strategies for the design of next-generation CAR-T therapies for haematologic and solid cancers.

This Review discusses the manipulation and use of human pluripotent stem cells and their progeny for the regeneration of the cardiovascular system.

This Review discusses the main diagnostic and therapeutic applications of synthetic gene circuits, and their translational prospects.

For cell therapies to transition from promises to products, increased efforts need to be put into the identification of the factors and biological mechanisms that affect safety and efficacy, and into the design of cost-effective methods for the harvesting, expansion, manipulation and purification of the cells.

Potent dendritic-cell cancer vaccines could be used to induce functional antitumour immunity without off-target toxicity.

An epicardial device that enables sustained and repeated administration of small molecules, macromolecules and cells directly to the epicardium provides therapeutic benefits in a rat model of myocardial infarction.